U.S. Neuropathic Pain Treatment Market, by Drug Type (Pain Relievers (NSAIDS, Opioids (Tramadol, Oxycodone, and Others)), Anti-seizure Medications (Gabapentin, Pregabalin, and Others), Topical Treatments, Antidepressants (Duloxetine, Amitriptyline, Escita

U.S. Neuropathic Pain Treatment Market, by Drug Type (Pain Relievers (NSAIDS, Opioids (Tramadol, Oxycodone, and Others)), Anti-seizure Medications (Gabapentin, Pregabalin, and Others), Topical Treatments, Antidepressants (Duloxetine, Amitriptyline, Escitalopram, and Others), and Others), by Indication (Diabetic Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Neuropathic pain can be a symptom or a side effect of a variety of diseases and ailments. These include different cancers and conditions such as multiple sclerosis and multiple myeloma. The nervous system may be impacted by chronic diabetes. Diabetes patients frequently experience numbness and lack of feeling in their limbs and fingers, followed by discomfort, burning, and stinging.

Market Dynamics

Increasing number of product approvals by regulatory authorities is expected to fuel growth of the U.S. neuropathic pain treatment market. For instance, in June 2020, Novaremed AG, a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had cleared an Investigational New Drug (IND) application to initiate its U.S.-based Phase 2 clinical study of the novel drug candidate, NRD135S.E1, for the treatment of painful diabetic peripheral neuropathy (DPN).

Increase in the number of facility expansions by market players is expected to boost the U.S. neuropathic pain treatment market growth over the forecast period. For instance, in May 2022, Teva Pharmaceutical Industries Ltd., a multinational pharmaceutical company, announced the expansion of its manufacturing facility in Dupnitsa, Bulgaria to facilitate the commercial production of essential medicines to meet current demand levels of disorders such as neuropathic pain treatment.

Rising awareness of peripheral neuropathy is expected to propel growth of the U.S. neuropathic pain treatment market over the forecast period. For instance, in May 2021, Averitas Pharma, a specialty pharmaceutical company, conducted a survey that aimed to raise awareness about the unmet medical needs of patients with diabetic nerve pain and to advocate for disease awareness and education.

Key features of the study:

• This report provides an in-depth analysis of the U.S. neuropathic pain treatment market, market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains an attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the U.S. neuropathic pain treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
• Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Johnson & Johnson, Dr. Reddy’s Laboratories Ltd., Pfizer, Inc., Cipla Inc., Lupin Limited, Averitas Pharma, Inc., NeuroBo Pharmaceuticals, Inc., LEXICON PHARMACEUTICALS, INC., Asahi Kasei Corporation, Vertex Pharmaceuticals Incorporated, and Biogen
• Insights from this report would allow marketers and the management authorities of the companies to make an informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The U.S. neuropathic pain treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. neuropathic pain treatment market

Detailed Segmentation:

• U.S. Neuropathic Pain Treatment Market, By Drug Type:
• Pain Relievers
• NSAIDS
• Opioids
• Tramadol
• Oxycodone
• Others
• Anti-seizure Medications
• Gabapentin
• Pregabalin
• Others
• Topical Treatments
• Antidepressants
• Duloxetine
• Amitriptyline
• Escitalopram
• Others
• Others
• U.S. Neuropathic Pain Treatment Market, By Indication:
• Diabetic Peripheral Neuropathy
• Chemotherapy-induced Peripheral Neuropathy
• Idiopathic Peripheral Neuropathy
• Others
• U.S. Neuropathic Pain Treatment Market, By Distribution Channel:
• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Company Profiles
• Teva Pharmaceutical Industries Ltd.*
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
• Eli Lilly and Company
• Johnson & Johnson
• Dr Reddy’s Laboratories Ltd.
• Pfizer, Inc.
• Cipla Inc.
• Lupin Limited
• Averitas Pharma, Inc.
• NeuroBo Pharmaceuticals, Inc.
• LEXICON PHARMACEUTICALS, INC.
• Asahi Kasei Corporation
• Vertex Pharmaceuticals Incorporated
• Biogen

“*” marked represents similar segmentation in other categories in the respective section.